Ads
related to: astrocytoma diagnosis- Glioma Treatment Option
Learn More About A Treatment
Option For Your Patients.
- FAQ Page
Visit Our FAQ Page To Answer
Your Questions About Treatment.
- Safety Information
HCPs, Learn More About The
Safety Of This Treatment.
- FDA-Approved
Learn About an FDA Approved
Glioma Treatment Option.
- Efficacy Information
Learn More About The Efficacy
Of This Glioma Treatment.
- Connect With A Rep
Schedule An Appointment
With A Representative Today.
- Glioma Treatment Option
Search results
Results From The WOW.Com Content Network
Astrocytoma causes regional effects by compression, invasion, and destruction of brain parenchyma, arterial and venous hypoxia, competition for nutrients, release of metabolic end products (e.g., free radicals, altered electrolytes, neurotransmitters), and release and recruitment of cellular mediators (e.g., cytokines) that disrupt normal parenchymal function. [2]
Subependymal giant cell astrocytoma (SEGA, SGCA, or SGCT) is a low-grade astrocytic brain tumor (astrocytoma) that arises within the ventricles of the brain. [1] It is most commonly associated with tuberous sclerosis complex (TSC). Although it is a low-grade tumor, its location can potentially obstruct the ventricles and lead to hydrocephalus.
Pilocytic astrocytoma (and its variant pilomyxoid astrocytoma) is a brain tumor that occurs most commonly in children and young adults (in the first 20 years of life). They usually arise in the cerebellum, near the brainstem, in the hypothalamic region, or the optic chiasm, but they may occur in any area where astrocytes are present, including the cerebral hemispheres and the spinal cord.
Initial presenting symptoms most commonly are headache, depressed mental status, focal neurological deficits, and/or seizures. [2] The growth rate and mean interval between onset of symptoms and diagnosis is approximately 1.5–2 years but is highly variable, [2] being intermediate between that of low-grade astrocytomas and glioblastomas. [2]
As the alternative name "diffuse astrocytoma" implies, the outline of the tumour is not clearly visible in scans, because the borders of the neoplasm tend to send out tiny microscopic fibrillary tentacles that spread into the surrounding brain tissue. These tentacles intermingle with healthy brain cells, making complete surgical removal difficult.
MRI of a patient with anaplastic astrocytoma. The WHO classification of tumours of the central nervous system is a World Health Organization Blue Book that defines, describes and classifies tumours of the central nervous system (CNS). Currently, as of 2023, clinicians are using the 5th edition, which incorporates recent advances in molecular ...
Ads
related to: astrocytoma diagnosis